FILING ANALYSIS · THURSDAY, NOVEMBER 12
Vivani Medical, Inc. VANI — 8-K: Results of Operations and Financial Condition
positive
Vivani Medical announced positive top-line results from a Phase 1 trial of its semaglutide implant, NPM-139, showing no treatment-related adverse events and comparable weight loss to Wegovy, a weekly semaglutide injection. The company plans to advance NPM-139 to a Phase 2 trial in 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →